ライフサイエンスコーパス: opioid peptide

1 s requires exocytosis of an endogenous kappa-opioid peptide.

2 neuropeptide that structurally resembles an opioid peptide.

3 fects are many times greater than unmodified opioid peptides.

4 e for opiate alkaloids and is insensitive to opioid peptides.

5 the presence of raised levels of endogenous opioid peptides.

6 the state of active sleep, are modulated by opioid peptides.

7 the production and/or release of endogenous opioid peptides.

8 xhibit structural features suggestive of the opioid peptides.

9 h is involved in terminating the activity of opioid peptides.

10 as the stimulatory effects of the endogenous opioid peptides.

11 d changes in hippocampal pathways containing opioid peptides.

12 sly been shown to improve bioavailability of opioid peptides.

13 ffect may involve feeding-induced release of opioid peptides.

14 mus is an important brain area that produces opioid peptides.

15 ed from a precursor protein in the family of opioid peptides.

16 hat exercise-induced increases in endogenous opioid peptides act in a manner similar to chronic admin

17 ick and Martinez to antagonism of endogenous opioid peptide action.

18 These results implicate endogenous opioid-peptide actions at mu opiate receptors in several

19 ese findings further suggest that endogenous opioid peptides activate mu opioid receptors to facilita

20 The intrinsic activities of all opioid peptide agonists and antagonists tested were not

21 h kelatorphan stabilizes putative endogenous opioid peptide agonists released by naloxone in GM1-trea

22 good assay for activation because endogenous opioid peptides all induce internalization.

23 Prodynorphin is processed into the opioid peptides, alpha-neoendorphin, and dynorphins A an

24 of possible autocrine and paracrine loops of opioid peptide and receptor expression have been identif

25 mu opioid receptors are targets of native opioid peptides and addictive analgesic drugs.

26 not show altered binding affinities for most opioid peptides and alkaloids tested.

27 Y (NPY) in the arcuate nucleus (ARC), and on opioid peptides and alpha-melanocyte stimulating hormone

28 are activated both by endogenously produced opioid peptides and by exogenously administered opiate c

29 Opioid peptides and glycyl-glutamine (Gly-Gln) have been

30 le for ECE2 in endocytic processing of delta opioid peptides and its effect on modulating delta opioi

31 eral inflamed tissue, both locally expressed opioid peptides and morphine can produce powerful analge

32 re the pharmacological targets of endogenous opioid peptides and morphine-like alkaloid drugs.

33 Effects of obesity on gene expression for opioid peptides and neuropeptide-Y (NPY) in the arcuate

34 IMG)-colon preparations to determine whether opioid peptides and neurotensin8-13 (NT8-13), the C-term

35 Opioid peptides and nociceptin/orphanin FQ (nociceptin)

36 accessible to released LE and possibly other opioid peptides and opiate drugs.

37 lular infiltration, and we examined synovial opioid peptides and opioid receptors by immunocytochemis

38 study was to examine the role of endogenous opioid peptides and opioid receptors specifically in the

39 nsfected cell models to a lesser degree than opioid peptides and other analgesic drugs, such as metha

40 id pharmacology and brain regional levels of opioid peptides and prodynorphin mRNA.

41 ucoprivation, lipoprivation and by different opioid peptides and receptor agonists.

42 The cloning of opioid peptides and receptors has led to the development

43 Expression of opioid peptides and receptors was measured using real-ti

44 l features and cellular actions with classic opioid peptides and receptors, but have distinct pharmac

45 trol regions of adult male songbirds contain opioid peptides and receptors, suggesting that opioids p

46 g 17beta-estradiol modulation of hippocampal opioid peptides and synaptic proteins while demonstratin

47 Opioid peptides and their receptors have been localized

48 suggest an important anticonvulsant role for opioid peptides and their receptors.

49 ch leads to an increased synaptic release of opioid peptides and to a naloxone-reversible hypoalgesic

50 by detecting c-Fos, an immediate early gene, opioid peptides and vesicular glutamate transporter 3 (V

51 ils of the delta opioid peptide (DOP), kappa opioid peptide, and mu opioid peptide receptors.

52 F), a tri-peptide contained in the dynorphin opioid peptide, and naloxone are neuroprotective at femt

53 ransmitters such as acetylcholine, dopamine, opioid peptides, and substance P in modulation of neurot

54 face, as measured by specific binding of the opioid peptide antagonist [(3)H]d-Phe((3)H)-Cys-Tyr-d-Tr

55 In the case of opioid peptides, antibodies are directed toward their C-

56 In contrast, the opioid peptides appear to influence the 'rewarding' aspe

57 growing body of evidence demonstrating that opioid peptides are an integral component of vertebrate

58 Opioid peptides are coreleased with catecholamines from

59 and evidence that members of this family of opioid peptides are endogenous agonists for the kappa op

60 Opioid peptides are involved in various essential physio

61 sexual behavior, suggesting that endogenous opioid peptides are released during mating.

62 lating agent for the (68)Ga, and two related opioid peptides are used as targeting ligands for improv

63 s in animals implicate endogenous release of opioid peptides as a mechanism for terminating partial a

64 SOPT2 accepts endogenous and synthetic opioid peptides as substrates, but nonpeptide opiate ant

65 ates the physiological effects of endogenous opioid peptides as well as the structurally distinct opi

66 roduce NO in the presence of morphine or the opioid peptides at similar concentrations.

67 drolysates further confirmed the presence of opioid peptide BCM-7.

68 investigated along with extensively studied opioid peptide beta-casomorphin using a human intestinal

69 The opioid peptide beta-endorphin plays a critical role in b

70 lpha-melanocyte-stimulating hormone, and the opioid peptide beta-endorphin.

71 ntagonism by antisera against the endogenous opioid peptide beta-endorphin.

72 As the opioid peptides beta-endorphin and enkephalin increase s

73 Feeding induced by the mu-sensitive opioid peptide, beta-endorphin (betaEND, 10 microg, i.c.

74 Natural residues of the dimeric opioid peptide Biphalin were replaced by the correspondi

75 howed little or no response to a panel of 21 opioid peptides but still signaled normally in response

76 Immune cell-derived opioid peptides can activate opioid receptors on periphe

77 ide genes, including those encoding the anti-opioid peptide cholecystokinin, pronociceptive Substance

78 beta-Endorphin is an opioid peptide cleaved from the precursor pro-hormone pr

79 nhance detection of perikarya containing the opioid peptides, colchicine (90-100 microg/kg) was admin

80 e demonstrated that these novel, fluorescent opioid peptide conjugates permit real-time visual tracki

81 psin L for biosynthesis of active enkephalin opioid peptide contrasts with its function in lysosomes

82 Opioid peptides costored with glutamate have emerged as

83 This is the first opioid peptide cyclized through the N-terminus that reta

84 opexin domain or claudin-1 siRNA, enables an opioid peptide ([D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin) a

85 Tolerance to the opioid peptide [d-Ala(2),N-MePhe(4),Gly-ol]-enkephalin w

86 te the effect of glycosylation on the cyclic opioid peptide [D-Cys(2,5),Ser(6),Gly(7)] enkephalin.

87 tal RPE cells by the uptake of the synthetic opioid peptide DADLE ((H-Tyr-D-Ala-Gly-Phe-D-Leu-OH) and

88 coumarinic acid (OMCA) cyclic prodrug of the opioid peptide DADLE ([D-Ala2,D-Leu5]-Enk, H-Tyr-D-Ala-G

89 torphan, an inhibitor of multiple endogenous opioid peptide-degrading enzymes, stabilizes endogenous

90 withdrawal is enkephalin, a five-amino acid opioid peptide derived from the proenkephalin A family.

91 With the use of two fluorescent opioid peptides, dermorphin-Bodipy Texas Red and dermorp

92 Opioid peptides did not stimulate NO release, indicating

93 delta opioid peptide (DOP) receptors are considered a therapeu

94 linked to the C-terminal tails of the delta opioid peptide (DOP), kappa opioid peptide, and mu opioi

95 the efficacy of analogues of the endogenous opioid peptide dynorphin (Dyn) A have focused on the N-t

96 They are activated by the endogenous opioid peptide dynorphin (DYN) and expressed at particul

97 OR) is the primary target for the endogenous opioid peptide dynorphin (DYN), and KORs reside within b

98 omatic dynorphin) is a novel analogue of the opioid peptide dynorphin A with a nonbasic N-terminus th

99 A proline scan at positions 2 and 3 of the opioid peptide dynorphin A(1-11)-NH(2) led to the discov

100 The structural properties of the endogenous opioid peptide dynorphin A(1-17) (DynA), a potential ana

101 chronic stress are encoded by the endogenous opioid peptide dynorphin acting on specific stress-relat

102 nditions of host stress, levels of the human opioid peptide dynorphin are elevated, triggering virule

103 The kappa opioid peptide dynorphin is present in hilar mossy fiber

104 the shell of the nucleus accumbens where the opioid peptide dynorphin is upregulated in treated rats

105 The opioid peptide dynorphin seemed to be one target through

106 red Orphanin FQ, a peptide homologous to the opioid peptide Dynorphin, and its receptor, the Orphanin

107 ects of CREB activation on expression of the opioid peptide dynorphin, we microinjected the kappa-opi

108 he hypocretin peptide is colocalized with an opioid peptide, dynorphin.

109 ating evidence indicates that the endogenous opioid peptides dynorphinA-(1-17) and dynorphinA-(1-13)

110 previously described interactions of several opioid peptides [e.g., proopiomelanocortin, enkephalin (

111 other opiate drugs of abuse, and endogenous opioid peptides effect analgesia and alter mood.

112 n estradiol-containing hypothalamic loci and opioid peptides, elicits morphine-induced antinociceptio

113 y, the tryptophan-containing noncationizable opioid peptides emerged with atypical structure and unex

114 The endogenous opioid peptide endomorphin-1 (1) was modified by attachm

115 e the effects of morphine and the endogenous opioid peptides, endomorphin-1 (EM-1) and endomorphin-2

116 These findings indicate that the opioid peptide ENK and epinephrine may elicit concerted

117 The results, therefore, indicate that the opioid peptide, ENK, and the inhibitory amino acid, GABA

118 spinal glutamatergic synapses colocalize the opioid peptide enkephalin (ENK), but the neurons to whic

119 The endogenous opioid peptide, enkephalin, and epincphrine are distribu

120 d a long-term elevation of the proconvulsive opioid peptide, enkephalin, in the rat hippocampus.

121 MOR are localized in neurons containing the opioid peptide, enkephalin, within the dorsolateral stri

122 Endogenous opioid peptides (EOPs) have been shown to play an import

123 Gly-Phe at the N terminus of most endogenous opioid peptides (EOPs).

124 ich include potentially important changes in opioid peptide expression and/or activity.

125 In contrast, opioid peptides failed to induce NO release, consistent

126 oenkephalin and that the generation of small opioid peptides from intermediates is mediated almost en

127 an allostatic state (decreased dopamine and opioid peptide function, increased corticotropin-releasi

128 These results show that native opioid peptides function in wound healing, and exert a t

129 uences of the cannabinoid receptor system on opioid peptide gene expression and on dopamine receptor

130 , as has been noted in energy-deprived rats, opioid peptide gene expression is decreased in the ARC o

131 ulatory effect on D(4) dopamine receptor and opioid peptide gene expression.

132 Opioid peptide genes, compared with their receptor genes

133 rters, we synthesized cyclic prodrugs of the opioid peptides H-Tyr-Ala-Gly-Phe-D-Leu-OH ([Ala2,D-Leu5

134 These data indicate that opioid peptides have a modulatory effect on NRGc-evoked

135 ding, although roles for specific endogenous opioid peptides have barely been addressed.

136 A series of opioid peptides have been developed in which the change

137 uld increase neurotransmission of endogenous opioid peptides (i.e., endorphins) in the nucleus accumb

138 O following treatment with morphine, but not opioid peptides (i.e., Met-enkephalin).

139 ide a route for more efficient production of opioid peptides in applications for chronic pain treatme

140 To test the hypothesis that opioid peptides in LC afferents are altered after chroni

141 ctrometry (LC-MS(3)) to determine endogenous opioid peptides in microdialysis samples collected in vi

142 expected on the basis of previous studies of opioid peptides in other avian species, including pigeon

143 Changes in the expression of these opioid peptides in presumed dopamine target neurons, whi

144 t significantly influence gene expression of opioid peptides in the ARC in either the lactating or th

145 cation stage involve changes in dopamine and opioid peptides in the basal ganglia.

146 NO)-dependent neuronal release of endogenous opioid peptides in the central nervous system.

147 By consequence, the inhibitory actions of opioid peptides in the dorsal vagal complex may depend o

148 In this opinion article, novel actions of mu-opioid peptides in the prefrontal cortex (PFC) that coul

149 characterize neuronal pathways that release opioid peptides in the rat dorsal horn, multiple-label i

150 mitter receptors that inhibit the release of opioid peptides in the spinal cord may play an important

151 Expression of dynorphin, an endogenous opioid peptide, increases with age and has been associat

152 Although opioid peptides induce internalization in vivo, there ar

153 ce of L-NAME (10(-4) M), indicating that the opioid peptide inhibition of the presynaptic release of

154 A decrease in endogenous opioid peptide inhibitory tone on the afternoon of proes

155 this receptor (opiate alkaloid selective and opioid peptide insensitive).

156 activation of the opiate alkaloid-selective, opioid peptide-insensitive micro3 receptor, and that fun

157 supports the opiate alkaloid selectivity and opioid peptide insensitivity of this receptor.

158 the tyramine moiety of alkaloids or Tyr1 of opioid peptides interacting with conserved residues in t

159 gs support a significant role for endogenous opioid-peptide interactions with mu opiate receptors in

160 ture, we sought to identify and describe the opioid peptides intrinsic to the RAIC by using immunohis

161 ber of synthetic compounds but does not bind opioid peptides; it is currently considered an orphan re

162 abeled for methionine-enkephalin (M-ENK), an opioid peptide known to be an endogenous ligand of the d

163 ts of dynorphin A can be reversed by a kappa-opioid peptide (KOP) receptor antagonist nor-binaltorphi

164 these were immunolabeled for the endogenous opioid peptide L-ENK.

165 ost-synaptic proteins, including PSD-95, and opioid peptides leu-enkephalin and dynorphin in the hipp

166 ationship between the MOR and the endogenous opioid peptide, Leu5-enkephalin (LE).

167 ctions that were also dually labeled for the opioid peptide leucine-enkephalin (L-ENK).

168 d the immunocytochemical localization of the opioid peptide leucine5-enkephalin (ENK) and the epineph

169 Such alterations in opioid peptide levels during opiate dependence may contr

170 of ovarian hormones on synaptic protein and opioid peptide levels in the aging hippocampus is unders

171 elective, conformationally constrained delta-opioid peptide ligand [(2S, 3R)-TMT1]DPDPE, a series of

172 following systemic administration of the new opioid peptide may be explained by activation of vagal a

173 We therefore suggest that endogenous opioid peptides may act as neuromodulators to regulate i

174 a demonstrate several sites where endogenous opioid peptides may interact with mu OR receptive sites

175 ide Y may initiate feeding for energy needs, opioid peptides may provide the rewarding aspects of eat

176 one, its neuroactive steroid metabolite, and opioid peptide mechanisms.

177 dynorphin demonstrates that this endogenous opioid peptide mediates the dysphoric effects of marijua

178 undertaken to investigate the effects of the opioid peptide Met-enkephalin (met-enk) on the release o

179 lin, 75 and 96% yields were obtained for the opioid peptides Met-RGL and Met-enk, respectively.

180 Opioid growth factor (OGF) is an endogenous opioid peptide ([Met(5)]enkephalin) that interacts with

181 An endogenous opioid peptide, [Met5]-enkephalin, termed opioid growth

182 A native opioid peptide, [Met5]-enkephalin, termed opioid growth

183 A native opioid peptide, [Met5]-enkephalin, termed opioid growth

184 In addition to neurotransmission, the native opioid peptide, [Met5]enkephalin, is a tonically active

185 The opioid peptide metenkephalin is a natural substrate of N

186 fe, was examined for immunoreactivity to the opioid peptide methionine enkephalin (mENK).

187 ester and unresponsive to stimulation by the opioid peptide methionine enkephalin.

188 ous axon terminals containing the endogenous opioid peptide, methionine5-enkephalin (ENK), that forme

189 temic administration of a novel glycosylated opioid peptide MMP-2200 (a.k.a. lactomorphin) was shown

190 The opioid peptide MMP-2200 blocked the apomorphine-induced

191 dence are mediated by its activity at the mu opioid peptide (MOP) receptor [1].

192 tch scratching, which can be inhibited by mu-opioid peptide (MOP) receptor and GRP receptor (BB2) ant

193 opamine neurons also express postsynaptic mu-opioid peptide (MOP) receptors.

194 to the development of ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP

195 there is a decrease in the synthesis of the opioid peptide mRNA and protein in the medullo-coerulear

196 moderate affinity and efficacy at nociceptin opioid peptide (NOP) receptors will have utility as a re

197 These results indicate that an endogenous opioid peptide, OGF, and its receptor are present and go

198 These results show that an opioid peptide, OGF, plays a direct role in the repair o

199 investigate the possible role of a specific opioid peptide on EtOH consumption.

200 imply that the central inhibitory action of opioid peptides on gastrointestinal function targets sel

201 es were designed to determine the actions of opioid peptides on synaptic transmission within the dors

202 vation in rats on the expression of striatal opioid peptide (OP) genes that subserve food motivation

203 y, we investigated the effects of one native opioid peptide, opioid growth factor ([Met(5)]-enkephali

204 The opioid peptide, Orphanin FQ/nociceptin (OFQ/N(1-17))(,)

205 phin and enkephalin knock-out mice that both opioid peptides play a positive role.

206 The opioid peptides PPD and PPE were expressed in the fetal

207 s been engineered to contain the cDNA for an opioid peptide precursor, human preproenkephalin, under

208 to food restriction since regional levels of opioid peptides, precursor mRNA, and receptor binding ha

209 Opioid peptides produce gastrointestinal inhibition and

210 dy PC2-dependent proteolytic events, such as opioid peptide production.

211 Previous studies showed that the delta-opioid peptide receptor (DOP-R) is dynamically regulated

212 elta (DOP), kappa (KOP) and nociceptin (NOP) opioid peptide receptor genes have been able to differen

213 ivo was explored by examining the effects of opioid peptide-receptor disruption using topical applica

214 e sarcolemma contains both catecholamine and opioid peptide receptors (OPRs).

215 peptide (DOP), kappa opioid peptide, and mu opioid peptide receptors.

216 e 1 (HIV-1), and recent studies suggest that opioid peptides regulate the function of macrophages fro

217 A1 neurons, uncovering regionally restricted opioid peptide release.

218 Rs) provides an ideal way to locate areas of opioid peptide release.

219 Protecting enkephalins, endogenous opioid peptides released in response to nociceptive stim

220 or (MOP) is activated by numerous endogenous opioid peptides, remains an attractive therapeutic targe

221 peptides are among the most kappa-selective opioid peptides reported to date, showing comparable or

222 The opioid peptides represent a major class of neurotransmit

223 response to dietary factors; release of the opioid peptides requires the Trpm5 ion channel.

224 c experiments demonstrated that intermediate opioid peptides secreted from SCH activate CXCR7, a beta

225 ver, the specific brain regions within which opioid peptide secretion contributes to the maintenance

226 Endogenous opioid peptides serve as growth factors in developing, r

227 Endogenous opioid peptides serve as growth factors in developing, r

228 Thus, the opioid peptides show either relatively low affinity or n

229 to mu OR-labeled dendrites may contain other opioid peptides, such as methionine-enkephalin.

230 e potential presence of other members in the opioid peptide superfamily.

231 re, these data support an active role of the opioid peptide system in the inhibition of the reproduct

232 hasize complex interplays between endogenous opioid peptides targeting mu-receptors, such as enkephal

233 tors, can cause the release of an endogenous opioid peptide that binds to mu opioid receptors within

234 illamine(2,5)-enkephalin (DPDPE) is a potent opioid peptide that exhibits a high selectivity for the

235 f the anionic residue Asp4 by Aib yielded an opioid peptide that fit two-site binding models for the

236 immunoperoxidase labeling of dynorphin A, an opioid peptide that is abundant in normal mossy fibers.

237 Beta-endorphin is an endogenous opioid peptide that is released during stress and has be

238 Dynorphin A is an endogenous opioid peptide that produces non-opioid receptor-mediate

239 d release of endogenous prodynorphin-derived opioid peptides that activated an anti-nociceptive KOR s

240 Enkephalins are endogenous opioid peptides that are derived from a pre-proenkephali

241 cine-enkephalin (L-ENK) are small endogenous opioid peptides that have been implicated in a wide vari

242 rphins represent a novel group of endogenous opioid peptides that have high affinity for the mu-opioi

243 t estrogen induces the release of endogenous opioid peptides that in turn activate the MOR.

244 The inability of opioid peptides to be transported through epithelial mem

245 bservations that demonstrated the failure of opioid peptides to promote cell rounding.

246 stinal repair, and sodium chloride-dependent opioid peptide transport.

247 es of human DPP III and its complex with the opioid peptide tynorphin, which rationalize the enzyme's

248 immunoassay for Leu-enkephalin, a mammalian opioid peptide, using a C-terminal aequorin-peptide fusi

249 e capability of a representative type of non-opioid peptides vasoactive intestinal peptide (VIP) in t

250 pathways, both of which contain and release opioid peptides, we tested the hypothesis that inactivat

251 overcome this obstacle, six new fluorescent opioid peptides were developed.

252 cocaine is causing the release of endogenous opioid peptides which activate mu opioid receptors withi

253 Dynorphin(1-8), an opioid peptide with high selectivity for the kappa-opioi

254 y injury increased the release in the RVM of opioid peptides with preferential affinity for the delta

255 s by comparing absolute expression levels of opioid peptides with their receptors, the largest neurop

256 Endogenous opioid peptides within the nucleus accumbens, a forebrai